Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension
Genetic evidence implicates the loss of bone morphogenetic protein type II receptor (BMPR-II) signaling in the endothelium as an initiating factor in pulmonary arterial hypertension (PAH). However, selective targeting of this signaling pathway using BMP ligands has not yet been explored as a therapeutic strategy. Here, we identify BMP9 as the preferred ligand for preventing apoptosis and enhancing monolayer integrity in both pulmonary arterial endothelial cells and blood outgrowth endothelial cells from subjects with PAH who bear mutations in the gene encoding BMPR-II, BMPR2. Mice bearing a heterozygous knock-in allele of a human BMPR2 mutation, R899X, which we generated as an animal model of PAH caused by BMPR-II deficiency, spontaneously developed PAH. Administration of BMP9 reversed established PAH in these mice, as well as in two other experimental PAH models, in which PAH develops in response to either monocrotaline or VEGF receptor inhibition combined with chronic hypoxia. These results demonstrate the promise of direct enhancement of endothelial BMP signaling as a new therapeutic strategy for PAH.
| Errataetall: |
CommentIn: Nat Rev Nephrol. 2015 Aug;11(8):445. - PMID 26122732 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Nature medicine - 21(2015), 7 vom: 12. Juli, Seite 777-85 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Long, Lu [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 28.09.2015 Date Revised 23.03.2024 published: Print-Electronic CommentIn: Nat Rev Nephrol. 2015 Aug;11(8):445. - PMID 26122732 Citation Status MEDLINE |
|---|
| doi: |
10.1038/nm.3877 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM249973960 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM249973960 | ||
| 003 | DE-627 | ||
| 005 | 20240323233536.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/nm.3877 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1342.xml |
| 035 | |a (DE-627)NLM249973960 | ||
| 035 | |a (NLM)26076038 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Long, Lu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.09.2015 | ||
| 500 | |a Date Revised 23.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Nat Rev Nephrol. 2015 Aug;11(8):445. - PMID 26122732 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Genetic evidence implicates the loss of bone morphogenetic protein type II receptor (BMPR-II) signaling in the endothelium as an initiating factor in pulmonary arterial hypertension (PAH). However, selective targeting of this signaling pathway using BMP ligands has not yet been explored as a therapeutic strategy. Here, we identify BMP9 as the preferred ligand for preventing apoptosis and enhancing monolayer integrity in both pulmonary arterial endothelial cells and blood outgrowth endothelial cells from subjects with PAH who bear mutations in the gene encoding BMPR-II, BMPR2. Mice bearing a heterozygous knock-in allele of a human BMPR2 mutation, R899X, which we generated as an animal model of PAH caused by BMPR-II deficiency, spontaneously developed PAH. Administration of BMP9 reversed established PAH in these mice, as well as in two other experimental PAH models, in which PAH develops in response to either monocrotaline or VEGF receptor inhibition combined with chronic hypoxia. These results demonstrate the promise of direct enhancement of endothelial BMP signaling as a new therapeutic strategy for PAH | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Growth Differentiation Factor 2 |2 NLM | |
| 650 | 7 | |a Monocrotaline |2 NLM | |
| 650 | 7 | |a 73077K8HYV |2 NLM | |
| 650 | 7 | |a JNK Mitogen-Activated Protein Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.11.24 |2 NLM | |
| 650 | 7 | |a Bone Morphogenetic Protein Receptors, Type II |2 NLM | |
| 650 | 7 | |a EC 2.7.11.30 |2 NLM | |
| 700 | 1 | |a Ormiston, Mark L |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Xudong |e verfasserin |4 aut | |
| 700 | 1 | |a Southwood, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Gräf, Stefan |e verfasserin |4 aut | |
| 700 | 1 | |a Machado, Rajiv D |e verfasserin |4 aut | |
| 700 | 1 | |a Mueller, Matthias |e verfasserin |4 aut | |
| 700 | 1 | |a Kinzel, Bernd |e verfasserin |4 aut | |
| 700 | 1 | |a Yung, Lai Ming |e verfasserin |4 aut | |
| 700 | 1 | |a Wilkinson, Janine M |e verfasserin |4 aut | |
| 700 | 1 | |a Moore, Stephen D |e verfasserin |4 aut | |
| 700 | 1 | |a Drake, Kylie M |e verfasserin |4 aut | |
| 700 | 1 | |a Aldred, Micheala A |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Paul B |e verfasserin |4 aut | |
| 700 | 1 | |a Upton, Paul D |e verfasserin |4 aut | |
| 700 | 1 | |a Morrell, Nicholas W |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature medicine |d 1995 |g 21(2015), 7 vom: 12. Juli, Seite 777-85 |w (DE-627)NLM074659804 |x 1546-170X |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2015 |g number:7 |g day:12 |g month:07 |g pages:777-85 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/nm.3877 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2015 |e 7 |b 12 |c 07 |h 777-85 | ||